Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nalotimagene carzoleucel
- Development stage
- Discontinued
- Lead developer
- MolMed
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Nalotimagene carzoleucel (Zalmoxis) is a cell-based gene therapy consisting of allogeneic T cells genetically modified with a retroviral vector encoding a truncated form of the human low-affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex virus type 1 thymidine kinase (HSV-TK Mut2) suicide gene. Developed by MolMed, it is indicated as an adjunctive treatment in adult patients with high-risk hematological malignancies undergoing haploidentical hematopoietic stem cell transplantation (HSCT). The suicide gene system allows for the selective elimination of the infused lymphocytes using ganciclovir or valganciclovir in the event of severe graft-versus-host disease (GvHD), thereby supporting immune reconstitution while providing a safety switch to control GvHD.
- Brand names
- Zalmoxis
- Other names
- HSV-TK gene-modified donor lymphocytesHSV-TK transduced donor lymphocytesTK-cellsHSV-TK gene-modified donor lymphocyte infusion
02
Targets
POLA1 (DNA polymerase alpha)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))
Beyond the preview
Go deeper on nalotimagene carzoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nalotimagene carzoleucel.